ABT-530: Additional Phase IIb data

Data from 34 treatment-naive or pegylated interferon treatment-experienced, non-cirrhotic patients with HCV genotypes 4, 5 or 6 infection in the open-label, international Phase IIb SURVEYOR-I trial showed that once-daily oral 300 mg ABT-493 plus 120 mg ABT-530 for 12 weeks led to an SVR 12 weeks after the end of treatment in 100% of patients. Data were presented at the European Association for the Study of the Liver meeting in Barcelona. AbbVie has previously reported data from the trial (see BioCentury, April 13, 2015; Oct. 26, 2015 & Nov. 23, 2015). ...